NUVB logo

NUVB Nuvation Bio Inc.

New York Stock Exchange · Biotechnology · Healthcare

$3.78
-0.12 (-3.08%)

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective sm…

Market Cap: $1.33Bwww.nuvationbio.com

Price

$6.60+48.31%
$4.21$5.04$5.87$6.70
Apr 30Aug 7

Social Signal Score

49
5d
—
30d
46
6 mentions
+0.0%
60d
47
7 mentions
+0.0%
90d
54
14 mentions
+0.0%
news: 14

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 2Sell 0Strong Sell 0
Avg price target$17+349.7%
Low $10Median $20High $21
Current Consensus

Revenue

$44.95M
$0.00$27.74M$55.49M$83.23M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-0.59
$-0.66–$-0.52
3 analysts
FY2026
$-0.40
$-0.41–$-0.37
7 analysts
FY2027
$-0.27
$-0.47–$-0.14
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David T. Hung
Sector
Healthcare
Industry
Biotechnology
Employees
310
Beta
1.73
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
0.09
www.nuvationbio.com